Medical Professionals

This webpage contains scientific information meant for medical professionals only.

  Improving cognition and daily functioning in Vascular Dementia

CognivAiD is indicated for patients with mild to moderate vascular dementia.

CognivAiD is a multi-herbal formulation comprising a combination of standardized extracts of 3 herbal ingredients:

Croci Stigma
Ginkgo Folium
Ginseng Radix et Rhizoma

Dosage & administration
The recommended dosage is 2 capsules, 2 times a day orally.

Side effects
Rare cases of headaches, gastrointestinal disturbances or allergic skin reactions.

Not recommended in pregnant and lactating women, and in individuals with bleeding tendency or are hypersensitive to ginkgo. Not recommended for concomitant use with anticoagulants/antiplatelets, and before surgery.


A targeted multi-modal Action

CognivAiD simultaneously targets the key pathological pathways of vascular dementia.


1. Seto, S., et al. (2017). Sailuotong prevents hydrogen peroxide (H2O2)-induced injury in EA.hy926 cells. International Journal of Molecular Sciences, 18(1), 95.

2. Yeon, S. Y., et al. (2020). Endothelium-Independent Vasodilatory Effect of Sailuotong (SLT) on Rat Isolated Tail Artery. Evidence-Based Complementary and Alternative Medicine, 2020, 1–10.

3. Zhang, Y., et al. (2019). Sailuotong Capsule Prevents the Cerebral Ischaemia-Induced Neuroinflammation and Impairment of Recognition Memory through Inhibition of LCN2 Expression. Oxidative Medicine and Cellular Longevity, 2019, 1–13.

    Sustained Improvement of Functional & Cognitive Domains in
    Vascular Dementia (VaD) With a Favourable Safety Profile



    1. Improves cognitive and executive functions1

    • Significant improvement of cognitive function based on VaDAS-Cog assessment as early as 3 months
    Long-term continuous improvement up to 1 year
    • Reproducible benefits seen in delayed-starter groups after switching from placebo to CognivAiD


    VaDAS-Cog: Vascular Dementia Assessment Scale Cognitive subscale


    2. Significant & clinically meaningful global improvement1

    Significant improvement in global condition of patients assessed by clinician with input of caregiver, based on ADCS-CGIC
    Divergence of outcomes between early- and delayed-starter groups was reversed as early as 3 months after switching from placebo to CognivAiD in delayed-starter groups
    • Sustained improvement for at least 1 year


    ADCS-CGIC: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change

    3. Safe and well-tolerated1,2

    • No significant difference in rate of adverse events in those taking CognivAiD vs placebo.





    1. Jia, J., et al. (2018). Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial. Alzheimer’s & dementia (New York, N. Y.), 4, 108–117.

    2. Steiner, G. Z., et al. (2016). The effect of Sailuotong (SLT) on neurocognitive and cardiovascular function in healthy adults: a randomised, double-blind, placebo controlled crossover pilot trial. BMC complementary and alternative medicine, 16, 15.


    Get in touch with us


    For more information, you may email your enquiries directly to [email protected]. Alternatively, you may fill in our enquiry form.


    Enquiry Form

    Disclaimer: CognivAiD™ is a trademark of Moleac and is referred to as ‘CognivAiD’ or ‘SaiLuoTong’ or ‘SLT’ in this website.

    Elderly couple looking at memories together

    Medical Professionals

    This page contains content meant for Medical Professionals Only.

    Please confirm that you are a Medical Professional.